Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2018

View Archived Issues

Astrocyte-driven inflammation is depression biomarker, target

Fungus is no fun for asthmatics

Senescent cells tangle up tau

PFN2 and GAMT are novel biomarkers of Charcot-Marie-Tooth disease

Methylation of the tumor suppressor TIPE3 corresponds to worse prognosis in nasopharyngeal carcinoma

Autoantibodies against TSP-4 are a diagnostic feature of osteoarthritis

Gilead Sciences presents the discovery of a novel Cyp inhibitor with potent anti-HCV activity

Phase I/II clinical trial of OT-58 recruiting patients with CBSDH

Sareum selects small-molecule inhibitor of TYK2/JAK1 for development for certain cancers

AI-powered platform for optimization of drug combination regimen in metastatic prostate cancer

Novavax opens phase II trial of NanoFlu

Vaccibody presents positive 6-month interim results from phase I/IIa study of VB10.16 immunotherapy

Eli Lilly and Company patents MAP3K5 inhibitors

Prelude Therapeutics divulges new PRMT5 inhibitors

Aldeyra announces positive data from phase IIb study of reproxalap topical ophthalmic solution

3M Pharmaceuticals synthesizes new cytokine biosynthesis inducers

Lupin identifies SCN9A blockers

Patient recruitment starts in phase III study of Ameluz plus BF-RhodoLED in superficial BCC

Lycera patents RORC agonists as IL-17 production enhancers

PAF-R antagonist XQ-1H well tolerated in phase I study

BriaCell achieves proof of concept with Bria-IMT in phase IIa breast cancer study

Newly developed ISOD mouse model mimics human disease

Janssen initiates phase III trial of guselkumab in pediatric psoriasis

Concert Pharmaceuticals amends protocol of phase IIa trial with CTP-543 in alopecia areata

Targovax reports interim tumor response data from phase I study of ONCOS-102 in advanced melanoma

MKP-5 inhibition as a novel therapeutic target for lung fibrosis

Discovery of novel Ref-1 inhibitors with the ability to block ocular neovascularization

Researchers develop viable murine model of cblC deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...